Focusing on solid tumor markers, 2B1, a bispecific murine monoclonal antibody with bispecificity for ErbB2 and CD16 was tested in a phase I clinical trial and showed responses in breast cancer patients [32]. The gene discussed is ERBB2; the disease is breast carcinoma.